Artivion, Inc. (CRY) Fund Overview

Artivion, Inc. (CRY) Healthcare & Pipeline Overview

Artivion, Inc. (CRY) develops, manufactures, and distributes medical devices and implantable tissues for cardiac and vascular surgery. With a focus on innovative solutions like BioGlue and On-X heart valves, Artivion serves physicians and hospitals globally, maintaining a significant presence in the medical device sector.

What Is the Investment Thesis for CRY?

With a market capitalization of $0.73 billion and a P/E ratio of 92.41, the company demonstrates growth potential. Key value drivers include continued adoption of its On-X heart valves and E-vita stent graft systems. Growth catalysts include expanding its product offerings and entering new geographic markets. However, investors should be aware of potential risks such as regulatory hurdles and competition from larger medical device companies.

Based on FMP financials and quantitative analysis

CRY Key Highlights

Market Cap of $0.73B reflects Artivion's valuation in the medical device market.

• P/E Ratio of 92.41 indicates investor expectations for future earnings growth.
• Gross Margin of 63.8% demonstrates strong pricing power and efficient cost management.
• Profit Margin of 2.5% suggests opportunities for improved operational efficiency and cost control.
• Beta of 1.53 indicates higher volatility compared to the overall market.

Who Are CRY's Competitors?

CRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRY's Key Strengths?

Innovative product portfolio with proprietary technologies.

• Established relationships with physicians and hospitals.
• Strong track record of regulatory approvals.
• Global distribution network.

What Are CRY's Weaknesses?

Relatively small market capitalization compared to major competitors.

• Low profit margin compared to industry peers.
• Dependence on a limited number of key products.
• High beta indicating higher volatility.

What Are the Key Risks for CRY?

Rich valuation — a P/E of 92.41 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.

• Product liability claims and recalls.
• Intense competition from larger medical device companies.
• Stringent regulatory requirements and potential delays in approvals.
• Economic downturns affecting healthcare spending.
• Fluctuations in currency exchange rates affecting international sales.

What Are CRY's Competitive Advantages?

• Proprietary Technology: Artivion's BioGlue and On-X heart valves are protected by patents and trade secrets, providing a competitive advantage.
• Established Relationships: The company has long-standing relationships with physicians and hospitals, creating customer loyalty.
• Regulatory Expertise: Artivion has a strong track record of obtaining regulatory approvals for its products, demonstrating its expertise in navigating the complex regulatory landscape.
• Specialized Services: Artivion offers specialized services such as cardiac preservation and pyrolytic carbon coating, differentiating it from competitors.

What Does CRY Do?

Artivion Inc., formerly known as CryoLife, Inc., was founded in 1984 and is headquartered in Kennesaw, Georgia. The company rebranded as Artivion in January 2022 to reflect its expanded focus and innovative product portfolio. Artivion specializes in manufacturing, processing, and distributing medical devices and implantable human tissues, serving physicians, hospitals, and healthcare facilities worldwide. Its core products include BioGlue, a surgical adhesive used in cardiac, vascular, and pulmonary procedures; On-X prosthetic heart valves, known for their design and biocompatibility; and a range of stent graft systems under the E-vita brand, used for treating aortic diseases. Artivion also offers cardiac preservation services, bovine pericardial patches (PhotoFix), synthetic vascular grafts, and hemostatic products like PerClot. Additionally, the company provides specialized services such as pyrolytic carbon coating for other medical device manufacturers. Artivion's products are used by cardiac, vascular, thoracic, and general surgeons, establishing the company as a key player in the medical device industry with a global reach.

What Products and Services Does CRY Offer?

• Manufactures and distributes medical devices for cardiac and vascular surgery.
• Processes and sells implantable human tissues.
• Offers BioGlue, a surgical adhesive used in various surgical applications.
• Provides On-X prosthetic heart valves and aortic prostheses.
• Offers E-vita stent graft systems for aortic disease treatment.
• Sells PerClot, an absorbable hemostat for surgical procedures.
• Provides cardiac preservation services.
• Offers pyrolytic carbon coating services for medical devices.

How Does CRY Make Money?

• Artivion generates revenue through the sale of medical devices and implantable tissues.
• The company also earns revenue from cardiac preservation services and pyrolytic carbon coating services.
• Artivion distributes its products through a direct sales force and a network of distributors.
• The company focuses on serving physicians, hospitals, and healthcare facilities globally.

What Industry Does CRY Operate In?

Artivion operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory oversight. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population and increasing demand for advanced medical technologies. Artivion competes with larger medical device companies and specialized players in the cardiac and vascular segments. The company's focus on niche markets and innovative products, such as its On-X heart valves and E-vita stent graft systems, positions it favorably within this competitive landscape.

Who Are CRY's Key Customers?

• Cardiac surgeons
• Vascular surgeons
• Thoracic surgeons
• Hospitals and healthcare facilities
• General surgeons

Return on equity for Artivion, Inc. stands at 2.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.3%, showing how much profit it generates from its asset base. CRY trades at a trailing price-to-earnings ratio of 92.41, above the Healthcare sector average of ~21.10x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.1%, the inverse of the P/E and a quick read on earnings relative to price.

CRY Financials

CRY Latest News

CRY Analyst Consensus

CRY MoonshotScore

CRY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources